Panelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.
“You're going to be able to use these catheters over time, for long periods," says Ana Lidia Flores-Mireles, PhD.
“Even if they're postmenopausal, we remove the ovaries, which puts them at a higher risk for other complications such as osteopenia,” says Laura Bukavina, MD, MPH, MSc.
"I'm able to really dedicate a lot of my time to patients and families for education," says Emily Sopko, CNP.
“There's definitely a lot of hype around the concept of artificial intelligence, and I think we're in the early phases of trying to figure out where it makes sense to adopt the technology and how to incorporate into clinical care,” says Yair Lotan, MD.
Dean Elterman, MD, discusses real-world outcomes of minimally invasive surgical therapies for benign prostate dysplasia, including improvements in quality of life, symptom relief, comparisons with clinical study results, and general patient feedback, while also sharing tips for building rapport and educating patients on their treatment options.
Dean Elterman, MD, compares minimally invasive surgical therapy (MIST) options for prostate treatment, discussing factors influencing choice, patient experience differences, and clinical and nonclinical factors such as prostate size, symptom severity, and patient preferences.
"I just want to underscore how important and how incredible it was to participate in this, because there was a lot of dialogue among the faculty and also the course participants," says Ziho Lee, MD.
"I think we could explore risk adjustment for surgeon reimbursement as a way of incentivizing providers and compensating them fairly for taking care of these more complex patients," says Victoria S. Edmonds, MD.
Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.
Panelists discuss how the STAAR study (Stein, 2018) indicates that the micronized abiraterone formulation results in lower average serum testosterone levels in 25% of patients compared to 17% with the originator formulation, potentially influencing treatment selection.
“So, while the natural epidemiological prevalence of disease is only 20% to 30%, we really should aim for studies where we can oversample the females to make sure that that medication truly is doing what it's doing in both males and females,” says Laura Bukavina, MD, MPH, MS.
"The patients who received SBRT were more likely to be Caucasian. We observed that far fewer Black men were treated with SBRT in our cohort," says Michael Stencel, DO.
“We are finding more and more information and evidence to support recommendations to try and reduce the infection rates,” says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.
"For more rural practices, for ureteroscopy, they also received lower reimbursement than urban practices," says Victoria S. Edmonds, MD.
“[This way, I can] educate myself and put myself in their shoes and suggest a treatment or a plan or an evaluation, and then find out what their feedback might be from a collaborative standpoint,” say Robert D. Hoy, MPAS, PA-C.
"Our hope is that if we can improve the experience of their initial treatment for urinary retention, then particularly the patients who actually need to catheterize to maintain their kidney health, they would not be afraid of catheterization," says Jennifer Ann Meddings, MD, MSc.
The key opinion leaders explore various treatment approaches for prostate cancer, including surgery, radiation, and hormone therapy, explaining how biomarker results influence their treatment choices. They also detail the specific criteria they use to select between treatment options based on biomarker testing outcomes.
The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.
This discussion explores the differences in the effects of abiraterone formulations when combined with prednisone or methylprednisolone.
This discussion provides an overview of abiraterone and the key differences between micronized and non-micronized formulations, including considerations for choosing between the two formulations.
“Unlike a lot of the societies within oncology, including ASCO or even NCCN, urology really does not do a good job at recommending mental health to our patients,” says Laura Bukavina, MD, MPH, MSc.
"The patients in these networks that were treated with SBRT certainly lived in areas with increased incomes," says Michael Stencel, DO.
"We have now realized that in some patients with a low number of metastatic sites, providing systemic treatment and providing some site-targeted treatment will provide lasting benefit or at least a temporary benefit that will help ameliorate the need for the systemic treatments or very intense systemic treatments," says Armine K. Smith, MD.
"Based on our work, it does show that ileal ureter replacement can be an effective long-term option for patients with long-segment ureteral stricture disease," says Ziho Lee, MD.
“While the medications might be covered, while the surgical treatment might be covered, we all know that mental health and dental care are one of those things where people have large copays, long delays to care, and it is very clear to see that from our study,” says Laura Bukavina, MD, MPH, MSc.
Experts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Stephen Freedland, MD, discusses the role of GnRH agonists and antagonists on improving cardiovascular outcomes in patients with prostate cancer.
Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.
